PIOMBINO DESE, Italy / May 23, 2024 / Business Wire / Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in two upcoming investor conferences.
The Company will present at the William Blair Growth Stock Conference in Chicago on Tuesday, June 4, 2024 at 4:00 p.m. (CT), and at the Jefferies Healthcare Conference in New York City on Thursday, June 6, 2024 at 9:30 a.m.(ET). A live webcast of each event will be available on the Company’s website at www.stevanatogroup.com under the "Investors" section. Replays of the webcasts will be available for approximately 90 days after each event.
About Stevanato Group
Founded in 1949, Stevanato Group is a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. The Group delivers an integrated, end-to-end portfolio of products, processes and services that address customer needs across the entire drug life cycle at each of the development, clinical and commercial stages. Stevanato Group’s core capabilities in scientific research and development, its commitment to technical innovation and its engineering excellence are central to its ability to offer value added solutions to clients.
For more information, please visit www.stevanatogroup.com.
Last Trade: | US$23.94 |
Daily Change: | -0.17 -0.71 |
Daily Volume: | 309,149 |
Market Cap: | US$1.190B |
November 11, 2024 November 05, 2024 October 01, 2024 August 29, 2024 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREAstria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load